A Case to Support the Continued Use of Rifampin in Clinical Drug-Drug Interaction Studies

Clinical Pharmacology & TherapeuticsEarly View Perspective A Case to Support the Continued Use of Rifampin in Clinical Drug–Drug Interaction Studies Joel P. Bercu, Joel P. Bercu orcid.org/0009-0004-6780-4721 Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, California, USASearch for more papers by this authorDavid J. Ponting, David J. Ponting orcid.org/0000-0001-6840-2629 Lhasa Limited, Leeds, UKSearch for more papers by this authorSharon L. Ripp, Sharon L. Ripp orcid.org/0009-0003-1056-8716 Pharmacokinetics, Dynamics & Metabolism, Pfizer Research & Development, Groton, Connecticut, USASearch for more papers by this authorKrista L. Dobo, Krista L. Dobo orcid.org/0000-0001-7129-1210 Drug Safety Research and Development, Pfizer Research & Development, Groton, Connecticut, USASearch for more papers by this authorRheem A. Totah, Rheem A. Totah orcid.org/0000-0003-1664-4874 Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USASearch for more papers by this authorJayaprakasam Bolleddula, Corresponding Author Jayaprakasam Bolleddula [email protected] orcid.org/0000-0003-4700-7819 Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA Correspondence: Jayaprakasam Bolleddula ([email protected])Search for more papers by this author Joel P. Bercu, Joel P. Bercu orcid.org/0009-0004-6780-4721 Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, California, USASearch for more papers by this authorDavid J. Ponting, David J. Ponting orcid.org/0000-0001-6840-2629 Lhasa Limited, Leeds, UKSearch for more papers by this authorSharon L. Ripp, Sharon L. Ripp orcid.org/0009-0003-1056-8716 Pharmacokinetics, Dynamics & Metabolism, Pfizer Research & Development, Groton, Connecticut, USASearch for more papers by this authorKrista L. Dobo, Krista L. Dobo orcid.org/0000-0001-7129-1210 Drug Safety Research and Development, Pfizer Research & Development, Groton, Connecticut, USASearch for more papers by this authorRheem A. Totah, Rheem A. Totah orcid.org/0000-0003-1664-4874 Department of Medicinal Chemistry, University of Washington, Seattle, Washington, USASearch for more papers by this authorJayaprakasam Bolleddula, Corresponding Author Jayaprakasam Bolleddula [email protected] orcid.org/0000-0003-4700-7819 Quantitative Pharmacology, EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA Correspondence: Jayaprakasam Bolleddula ([email protected])Search for more papers by this author First published: 18 March 2024 https://doi.org/10.1002/cpt.3256Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICTS OF INTEREST JPB is an employee of Gilead Sciences, Inc. SLR and KLD are employees of Pfizer. JB is an employee of EMD Serono. JPB, SLR, KLD, and JB holds stock in their respective companies. DJP is an employee of Lhasa Limited, a nonprofit organization. RT is an employee of the University of Washington and declares no conflict of interest. Supporting Information Filename Description cpt3256-sup-0001-TableS1.docxWord 2007 document , 36.8 KB Table S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. References 1 ICH Guideline M12 on drug interaction studies (Step 2b). . Accessed December 14, 2023. Google Scholar 2Wang, Y.M., Ong, S.S., Chai, S.C. & Chen, T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin. Drug Metab. Toxicol. 8, 803–817 (2012). 10.1517/17425255.2012.685237 CASPubMedWeb of Science®Google Scholar 3Bercu, J.P. et al. Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs). Regul. Toxicol. Pharmacol. 142, 105415 (2023). 10.1016/j.yrtph.2023.105415 CASPubMedWeb of Science®Google Scholar 4 Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products . Accessed December 14, 2023. Google Scholar 5Muller, L. et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Regul. Toxicol. Pharmacol. 44, 198–211 (2006). 10.1016/j.yrtph.2005.12.001 CASPubMedWeb of Science®Google Scholar 6Felter, S.P. et al. A proposed framework for assessing risk from less-than-lifetime exposures to carcinogens. Crit. Rev. Toxicol. 41, 507–544 (2011). 10.3109/10408444.2011.552063 CASPubMedWeb of Science®Google Scholar 7Niemi, M., Backman, J.T., Fromm, M.F., Neuvonen, P.J. & Kivistö, K.T. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819–850 (2003). 10.2165/00003088-200342090-00003 CASPubMedWeb of Science®Google Scholar 8Bolleddula, J., Gopalakrishnan, S., Hu, P., Dong, J. & Venkatakrishnan, K. Alternatives to rifampicin: a review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies. Clin. Transl. Sci. 15, 2075–2095 (2022). 10.1111/cts.13357 CASPubMedWeb of Science®Google Scholar 9Haarst, A.V., Smith, S., Garvin, C., Benrimoh, N. & Paglialunga, S. Rifampin drug-drug-interaction studies; reflections on the nitrosamine impurities issue. Clin. Pharmacol. Ther. 113, 816–821 (2023). 10.1002/cpt.2652 PubMedGoogle Scholar 10Asaumi, R. et al. Comprehensive PBPK model of rifampicin for quantitative prediction of complex drug-drug interactions: CYP3A/2C9 induction and OATP inhibition effects. CPT Pharmacometrics Syst. Pharmacol. 7, 186–196 (2018). 10.1002/psp4.12275 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation